Department of Pediatrics, Section of Pediatric Emergency Medicine, University of Colorado Denver, Children's Hospital Colorado, Denver, CO, USA.
Acad Emerg Med. 2012 Oct;19(10):1145-50. doi: 10.1111/j.1553-2712.2012.01450.x. Epub 2012 Sep 25.
Ketamine is one of the most commonly used procedural sedation and analgesia (PSA) agents in pediatric emergency departments (PEDs). It is considered a very safe and reliable agent, with limited respiratory suppression, hemodynamic effects, and adverse outcomes. However, physicians are often reluctant to use ketamine for patients with eye injuries due to a concern that ketamine might increase intraocular pressure (IOP). The objective was to measure IOP in previously healthy children receiving ketamine for PSA for a reason other than eye injury.
This was a prospective noninferiority study of patients seen in an academic tertiary care children's hospital emergency department (ED) who required ketamine for PSA. The authors measured IOP in the right eye as soon as possible after ketamine had been administered and then at 2.5, 5, and 10 minutes after ketamine had been administered.
Eighty patients were enrolled (28 between 1 and 5 years of age, 26 between 6 and 10 years, 26 between 11 and 15 years); 49 (61%) were male. Procedures requiring PSA included fracture/dislocation reduction (63%), abscess incision and drainage (16%), laceration repair (11%), dental abscess incision and drainage (6%), and other (4%). The mean total ketamine dosage was 1.6 mg/kg (95% confidence interval [CI] = 1.4 to 1.7). The mean initial IOP was 17.5 mm Hg (95% CI = 16.4 to 18.6 mm Hg) and at 2.5 minutes was 18.9 mm Hg (95% CI = 17.9 to 19.9 mm Hg). The mean difference was 1.4 mm Hg (95% CI = 0.4 to 2.4 mm Hg). Using a noninferiority margin of 2.6 mm Hg (15%), noninferiority (no significant elevation in IOP) was demonstrated with 95% confidence between the first and second readings.
Ketamine does not significantly increase IOP in pediatric patients without eye injuries receiving typical PSA dosages in the PED. Further study should assess its safety in patients with ocular injury.
氯胺酮是小儿急诊科(PED)中最常用的程序镇静和镇痛(PSA)药物之一。它被认为是一种非常安全可靠的药物,呼吸抑制、血液动力学效应和不良后果有限。然而,由于担心氯胺酮会增加眼内压(IOP),医生通常不愿意为眼部受伤的患者使用氯胺酮。目的是测量因眼部受伤以外的其他原因接受 PSA 的健康儿童的 IOP。
这是一项前瞻性非劣效性研究,纳入在学术性三级儿童保健医院急诊科就诊、因 PSA 需要氯胺酮的患者。作者在给予氯胺酮后尽快测量右眼的 IOP,然后在给予氯胺酮后 2.5、5 和 10 分钟测量 IOP。
共纳入 80 例患者(1-5 岁 28 例,6-10 岁 26 例,11-15 岁 26 例);49 例(61%)为男性。需要 PSA 的操作包括骨折/脱位复位(63%)、脓肿切开引流(16%)、裂伤修复(11%)、牙周脓肿切开引流(6%)和其他(4%)。氯胺酮总剂量平均为 1.6mg/kg(95%置信区间[CI] 1.4-1.7)。初始平均 IOP 为 17.5mmHg(95%CI 16.4-18.6mmHg),2.5 分钟时为 18.9mmHg(95%CI 17.9-19.9mmHg)。平均差值为 1.4mmHg(95%CI 0.4-2.4mmHg)。使用 2.6mmHg(15%)的非劣效性边界,在第一次和第二次读数之间,95%置信区间显示非劣效性(IOP 无显著升高)。
在接受 PED 典型 PSA 剂量的无眼部受伤的儿科患者中,氯胺酮不会显著增加 IOP。进一步的研究应评估其在眼部受伤患者中的安全性。